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RESUMEN 
Los índices cuadráticos tridimensionales (3D)-quirales 
no-estocásticos y estocásticos basados en relaciones de 
átomos son aplicados para predecir la afinidad de unión 
de 26 estereoisómeros del fenoterol con el receptor adre-
nérgico β2 (β2-AR). La predicción de la afinidad de unión al 
β2-AR de los estereoisómeros se realizó mediante le em-
pleo de la regresión lineal múltiple. Dos modelos QSAR 
estadísticamente significativos son obtenidos cuando 
los índices 3D-quirales no-estocásticos (R2 = 0.941 y s = 
0.19) y estocásticos (R2 = 0.947 y s = 0.18) son empleados. 
Ambos modelos mostraron un adecuado poder predicti-
vo (evaluado por el procedimiento de validación cruzada 
dejando-uno-fuera), alcanzando valores de q2 = 0.909 (scv 
= 0.219) y q2 = 0.917 (scv = 0.208), respectivamente. Estos 
modelos fueron superiores a otro modelo 3D-QSAR obte-
nido previamente por otros investigadores empleando el 
método CoMFA (R2 = 0.920, q2 = 0.847 y scv = 0.309). Los 
resultados de nuestro trabajo demuestran la utilidad de 
nuestros descriptores topológicos para la predicción de la 
actividad biológica, incluso en los estudios en los cuales la 
configuración tridimensional de los compuestos juega un 
papel importante en la actividad biológica. 
Palabras Claves: índices cuadráticos 3D-quirales no-es-
tocásticos y estocásticos basados en relaciones de áto-
mos, receptor adrenérgico-β2, afinidad de unión, estereoi-
sómeros del fenoterol, 3D-QSAR.
SUMMARY 
The non-stochastic and stochastic atom-based three di-
mensional (3D)-chiral quadratic indices are applied to pre-
dict the binding affinities of 26 stereoisomers of fenoterol 
with the β2-adrenoceptor (β2-AR). The prediction of β2-AR 
binding affinities of the stereoisomers is carried out by 
multiple linear regression analysis. Two statistically signifi-
cant QSAR models are obtained when non-stochastic (R2 
= 0.941 and s = 0.19) and stochastic (R2 = 0.947 and s = 
0.18) 3D-chiral quadratic indices are used. These models 
show adequate predictive power (assessed by the leave-
one-out cross-validation experiment), yielding values of q2 
= 0.909 (scv = 0.219) and q
2 = 0.917 (scv = 0.208), respec-
tively. These models compare favorably with a 3D-QSAR 
equation obtained with the CoMFA method (R2 = 0.920, q2 
= 0.847 and scv = 0.309). The results of our work demon-
strate the usefulness of our topological approach for the 
prediction of biological activity, even in those studies in 
which the three-dimensional configuration of the chemi-
cals play an important role in the bioactivity.
Keywords: non-stochastic and stochastic atom-based 
3D-chiral quadratic indices, β2-adrenoceptor, binding af-
finity, fenoterol stereoisomer, 3D-QSAR.
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RESUM
Els índexs quadràtics tridimensionals (3D)-quirals no-esto-
càstics i estocàstics basats en relacions d’àtoms són apli-
cats per predir l’afinitat d’unió de 26 estereoisòmers del 
fenoterol amb el receptor adrenèrgic β2  (β2-AR). La predic-
ció de l’afinitat d’unió a l’β2-AR dels estereoisòmers es va 
realitzar mitjançant l’ús de la regressió lineal múltiple. Quan 
s’utilitzen els índexs 3D-quirals no-estocàstics (R2 = 0941 
i s = 0,19) i estocàstics (R2 = 0947 i s = 0,18) s’obtenen 
dos models QSAR estadísticament significatius. Tots dos 
models van mostrar un poder predictiu adequat (avaluat 
pel procediment de validació creuada deixant-un-fora), 
assolint valors de q2 = 0909 (SCV= 0,219) i q
2 = 0917 (SCV = 
0,208), respectivament. Aquests models van ser superiors 
a un altre model 3D-QSAR obtingut prèviament per altres 
investigadors utilitzant el mètode COMFER (R2 = 0.920, 
q2 = 0847 i SCV= 0,309). Els resultats del nostre treball de-
mostren la utilitat dels nostres descriptors topològics per a 
la predicció de l’activitat biològica, fins i tot en els estudis 
en els quals la configuració tridimensional dels compostos 
juga un paper important en l’activitat biológica.
Paraules clau: índexs quadràtics 3D-quirals no-estocàs-
tics i estocàstics basats en relacions d’àtoms, receptor 




lethyl]-amino]ethyl]-1,3-benzenediol, is a β2-adrenoceptor 
(β2-AR) agonist
1 that is used for the treatment of asthma2 
and may also be useful in the treatment of congestive heart 
failure.3 This has been suggested by results from studies in 
cardiomyocytes from an animal model of congestive heart 
failure, the spontaneously hypertensive rat.3, 4
Fenoterol shows two chiral centers and exists as four stere-
oisomers. The clinically used drug, rac-fenoterol, is a race-
mic mixture of the (R,R) and (S,S) isomers of compound 
1 (see Fig. 1).5 In 1978, Kaiser and co-workers performed 
initial displacement binding studies using the separate 
enantiomers, in rat erythrocytes.6 The data demonstrated 
that (R,R)-1 displaced the marker ligand [3H]-dihydroalpre-
nolol with a Kd of 2.88x10
-6 M, rac-1 had a Kd of 5.79x10
-
5M, and (S,S)-1 had no measurable specific binding.6 In a 
recent study Beigi et al. confirm the enantioselectivity of 
the β2-AR; they also examined the pharmacological effects 
of (R,R)-1 and (S,S)-1 using cardiomyocyte contractility in 
freshly isolated adult rat cardiomyocytes.7 In this model, 
(R,R)-1 increased the maximum contractile response from 
(265±11.6%) to (306±11.8%) of resting cell length (p < 
0.05) and reduced EC50 from (-7.0±0.27) to (-7.1±0.20) log 
[M] (p < 0.05), while (S,S)-1 had no significant effect.
Moreover, another study was carried out recently by Jo-
zwiak and co-workers.5 They synthesized and character-
ized a series of derivatives of 1 (compounds 2-7 in Figure 
1), to determine the effect of altering the 4-hydroxyphenyl 
moiety and of the removing of the second chiral center. 
Furthermore, they developed a QSAR model using com-
parative molecular field analysis (CoMFA). In this work, the 
authors concluded that the R-configuration is favored for 
functional activity at β-AR receptors, which is consistent 
with previous models and experimental data.8-11 In this sig-
nificant research, effort was made to find models of the 
relationship between the structure of β-adrenergic agonist 
and their binding affinities. Such models could assist re-
searchers in understanding the structural basis for bind-
ing, as well as in providing a basis for the development 
of new compounds with β2-AR selectivity, which could be 
tested for their use in the treatment of congestive heart 
failure.
Topological indices (TIs) have been extensively used in the 
past in drug design studies and in the modeling of many 
properties/activities. For example Bonchev et al. used TIs 
to model anticancer action in some works12, 13 and Gal-
vez et al. made use of TIs to select and design new ac-
tive compounds in different therapeutical scopes, with a 
rather high efficiency level.14, 15 Others studies were also 
performed to identify and design compounds with antimi-
crobial16 and non-narcotic analgesic17 action.
In recent times, a novel scheme in the rational –in silico- 
molecular design and to in QSAR/QSPR has been intro-
duced by our research group TOMOCOMD (acronym of 
TOpological MOlecular COMputer Design). It calculates 
several new families of 2D, 3D-Chiral (2.5) and 3D (geo-
metric and topographical) non-stochastic and stochastic 
atom- and bond-based molecular descriptors, based on 
algebraic theory and discrete mathematics. They are de-
noted quadratic, linear and bilinear indices and have been 
defined in analogy to the corresponding mathematical 
maps.18-20 These approaches describe changes in the elec-
tron distribution with time throughout the molecular bac-
kbone, and they have been successfully employed in the 
prediction of several physical, physicochemical, chemical, 
biological, toxicological and pharmacokinetic properties of 
organic compounds.21-27 Besides, these indices have been 
extended to consider three-dimensional features of small/
medium-sized molecules based on the trigonometric 3D-
chirality correction factor approach.28-33 In earlier publi-
cations, we have obtained rather promising results when 
stochastic and non-stochastic atom-based 3D-chiral qua-
dratic, linear and bilinear indices were applied to three of 
the chiral datasets most commonly used.28-33 Taking into 
account the promissory results obtained with the atom-
based 3D-chiral quadratic indices,29, 30 the present report is 
written with two objectives in mind. First, to develop QSAR 
models, using the non-stochastic and stochastic atom-
based 3D-chiral quadratic indices, in order to predict the 
binding affinities of the fenoterol stereoisomers with the 
β2-AR receptor and, second, to compare our results with 
those previously obtained by other researchers using the 
CoMFA method.5
MATERIALS AND METHODS
The atom-based non-stochastic and stochastic quadratic 
indices has been explained elsewhere in some detail,20, 29, 
30 however here we are going to give a brief explanation 
about it. If a molecule consists of  atoms (vector of ), 
then the  total (whole) quadratic indices are calculated 
as quadratic forms on in a canonical basis set. Spe-
cifically, the  non-stochastic and stochastic atom-based 
quadratic indices for a molecule,  ( x ) and  ( x ), re-
spectively, are computed from the following equations:
                   (1)        
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                     (2)       
where, n is the number of atoms of the molecule, and 
,…,  are the coordinates or components of the “molecu-
lar vector” ( x ) in a canonical (‘natural’) basis set of . 
In this basis set, the coordinates of any vector x , namely 
,…, , coincide with the components of this vector.34, 35 
Therefore, those coordinates can be considered as weights 
(atomic labels) of the vertices in the molecular pseudog-
raph. The coefficients  and  are the elements of the 
 power of the matrices  and , correspondingly, 
in the molecular pseudograph.20, 29, 30
In addition to total quadratic indices, computed for the 
whole molecule, a local-fragment (atomic and atom type 
as well as group) formalism can be developed. These de-
scriptors are termed local non-stochastic and stochastic 
quadratic indices,  and , correspondingly.20, 29, 
30 The definition of these descriptors is as follows:
                     (3)    
                 (4)  
where n is the number of atoms (atomic nuclei) in the frag-
ment of interest and  is the  element of the 
row “ ” and column “ ” of the local matrix . This 
matrix is extracted from the  matrix and contains 
information referred to the vertices (atomic nuclei) of the 
specific molecular fragments and also of the molecular 
environment in  steps. The matrix  with elements 
 is defined as follows: 
 if both  and  are atoms con-
tained within the molecular fragment 
 if either  or  is an atom contained within 
the molecular fragment   
= 0 otherwise
Moreover, the atom-type quadratic indices can also be cal-
culated as local MDs. In the atom-type quadratic indices 
formalism, each atom in the molecule is classified into an 
atom type (fragment), such as –F, -OH, =O, -CH3, and so 
on. These local MDs can be calculated for a chemical (or 
functional) group in the molecule, such as heteroatoms (O, 
N and S in all valence states and including the number of 
attached H atoms), hydrogen bonding (H-bonding) to heter-
oatoms (O, N and S in all valence states), halogen atoms (F, 
Cl, Br and I), all aliphatic carbon chains (several atom types), 
all aromatic atoms (aromatic rings), and so on.20, 29, 30
Furthermore, due to that the total and local, non-stochastic 
and stochastic quadratic indices, as defined above, can-
not codify any information about 3D molecular structure. In 
order to solve this problem we introduced a trigonometric 
3D-chirality correction factor in the molecular vector x , in 
previous works.29, 30 In these sense, a chirality molecular 
vector is obtained (* x ), where the components of x  (for 
instance, Mulliken electronegativity (xA) of the atom A) are 
substituted by the following term   
The trigonometric 3D-chirality correction factor uses a 
dummy variable,  and an integer parameter, :28, 30
Compound
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Figure 1. The structures of the stereoisomers of Fenoterol and compounds 2-7 synthesized and tested by Jozwiak et al.5  
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 = 1 and  is an odd number when  has  (rectus), 
E (entgegen), or a (axial) notation according to the Cahn-
Ingold-Prelog (IUPAC) rules                                             (5)
= 0, and  is an even number, if  does not have 3D spe-
cific enviroment, 
= -1, and  is an odd number when  has S (sinister),Z 
(zusammen), or e (equatorial) notation according to Cahn-
Ingold-  Prelog rules.
Thus, this 3D-chirality factor sin  takes differ-
ent values in order to codify specific stereochemical infor-
mation such as chirality, Z/E isomerism, and so on. This 
factor takes, therefore, values in the following order 1 > 
0 > -1 for atoms that have specific 3D environments. A 
very interesting point is that the present 3D-chiral descrip-
tor reduces to simple (2D) non-stochastic and stochastic 
quadratic indices, for molecules without specific 3D char-
acteristics because sin  being  zero or any 
integer (particularly even) number. Therefore, when all the 
atoms in the molecule are not chiral, these chiral MDs do 
not change upon the introduction of this factor. This means 
that * x  = x  and, thus, 28, 30
On the other hand, the structures of the molecular set used 
in this study are depicted in Figure 1. This molecular data-
set was recently introduced by Jozwiak and co-workers;5 
the respective binding affinities were also determined by 
these authors. The molecular structure of each compound 
was codified using the non-stochastic and stochastic at-
om-based 3D-chiral quadratic indices.29, 30 In the present 
report, we characterized every atomic nucleus with the fol-
lowing parameters (weighting scheme): atomic mass (M), 
atomic polarizability (P), atomic Mulliken electronegativity 
(K), van der Waals atomic volume (V), plus the atomic elec-
tronegativity in Pauling scale (G).36-39
The following descriptors were calculated in this work:
(i)  total 3D-chiral quadratic indices, not considering and 
considering H atoms in the molecular pseudograph (G) 
 and  respectively].
(ii)  local (atom-type = heteroatoms: S, N, O) 3D-chiral 
quadratic indices, not considering and considering H 
atoms in the molecular pseudograph (G)  and 
, respectively]. These local descriptors are puta-
tive H-bonding acceptors.
(iii)  local (atom type = H atoms bonding to heteroatoms: 
S, N, O) 3D-chiral quadratic indices, considering H atoms 
in the molecular pseudograph (G) . These local 
descriptors are putative H-bonding donors. 
The  stochastic total    
3D-chiral quadratic indices were also computed. All these 
molecular descriptors were calculated with the TOMO-
COMD-CARDD software.40
Statistical analysis was carried out with the STATISTICA 
software.41 A multiple linear regression (MLR) was carried 
out to predict the binding affinity of the fenoterol stereoiso-
mers data set. The quality of the models was determined 
examining the regression’s statistical parameters. Namely, 
the quality of the models was determined by examining 
the determination coefficients (also known as square re-
gression coefficients, R2), Fisher-ratio’s p-level [p(F)] and 
standard deviation of the regression (s).42 An important 
aspect of QSAR modeling is the development of tools for 
the validation of the model. Good direct statistical criteria 
to fit the dataset are not a guarantee that the model could 
make accurate predictions. The leave-one-out (LOO) press 
statistics  have been used as a means of demon-
strating predictive capability.
RESULTS AND DISCUSSION
The purpose of this study was to develop quantitative 
models which permit the prediction of the binding affinities 
of the fenoterol stereoisomers derivatives with the β2-AR 
receptor from the molecular structure by using a combina-
torial approach of atom-based 3D-chiral quadratic indices 
and multiple linear regression method. The experimental 
binding affinities of the fenoterol stereoisomer derivatives 
were taken from Jozwiak et al,5 and Table 1 summarize the 
entire studied set with the observed and predicted bind-
ing affinities. The obtained QSAR models are given below 
together with their statistical parameters:
 = 1.06(±0.41) +2.19x10-5(±0.18x10-5)      
         
–1.14x10-5(±0.10x10-5)  +1.78x10-6(±0.16x10-6)  
     
 –2.11x10-3(±0.55x10-3)                  (6)
N = 26          R = 0.970       R2 = 0.941        F(4,21) = 83.996 
 = 0.19    < 0.0001        = 0.909    = 0.219        
 = 6.73x10-2(±0.50) +0.8601(±0.16) 
       –0.90(±0.16)  
       +2.79(±0.51)   –2.71(±0.52)           (7) 
N = 26         R = 0.973        R2 = 0.947       F(4,21) = 94.688 
 = 0.18         < 0.0001     = 0.917      = 0.208        
where N is the size of the data set, R2 is the square correla-
tion coefficient (determination coefficient),  is the stand-
ard deviation of the regression, F is the Fischer ratio and  
( ) is the square correlation coefficient (standard devia-
tion) of the cross-validation performed by the LOO proce-
dure. These statistics indicate that these models are ap-
propriate for the description of the chemicals studied here.
As can be seen, both models were developed with only 
four variables and they are able to explain more than 94% 
of the variance of the experimental binding affinity values, 
with low values of standard deviation  = 0.19 and  = 0.18 
for models 6 and 7, correspondingly. On the other hand, 
the model previously obtained by Jozwiak et al.5, using 
CoMFA, explains only 92% of the experimental data with 
 = 0.223. The predictability and stability of the obtained 
models (Eqs. 6 and 7) to data variation was carried out 
here by means of LOO cross-validation. 
These models showed a cross-validation square corre-
lation coefficient of 0.909 (  = 0.219) and 0.917 (  = 
0.208), respectively, while the CoMFA model showed a 
q2 value of 0.847 (  =0.309). Notice that the results ob-
tained with the present QSAR method, non-stochastic and 
stochastic atom-based 3D-chiral quadratic indices com-
pare favourably to those previously achieved with CoMFA. 
The enantioselective binding preference for β2-ARs, with 
the R-configuration at the stereogenic center containing 
the β-OH moiety, has been established in previous re-
ports.8-11 Therefore, a comparison between the R,R-iso-
mers could be an important topic (see Table 1). The result 
of this comparison showed that (R,R)-5 had the highest 
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relative affinity of the tested compounds, followed by 
(R,R)-2 stereoisomer; these values are slightly greater than 
the predicted value for the (R,R)-1, although in experimen-
tal assays the order was 5 >1 > 2 for these isomers. These 
results are quite similar to those obtained by Jozwiak et 
al.5 According with the predicted and experimental values, 
isomers 5 and 2 can be proposed as new lead-compounds 
to develop new drugs with agonist action in the β2-ARs. 
Studies of chemical optimization of these compounds 
should be carried out in the future.
Furthermore, we can see that for all the cases the pre-
dicted values for isomers (R,S) were lower than for the iso-
mers (R,R); so, we can say that a change of the chirality 
from R to S in the second chiral atom causes a decay of 
the affinity of the chemical for the receptor. These results 
for the prediction are in completely agreement with the ex-
perimental results achieved by other researchers. 
Table 1. The pKi predicted with non-stochastic and stochastic atom-based 3D-chiral quadratic indices
Compound Observeda PredictedNon-stochasticb Residual Predicted  Stochastic c Residual
R,R-1 6.460 5.979 0.481 6.127 0.333
S,S-1 4.560 4.764 -0.204 4.784 -0.224
R,S-1 5.430 5.541 -0.111 5.380 0.050
S,R-1 4.990 4.971 0.019 5.052 -0.062
R,R-2 6.320 6.168 0.152 6.354 -0.034
S,S-2 4.800 4.955 -0.155 5.033 -0.233
R,S-2 5.710 5.733 -0.023 5.629 0.081
S,R-2 5.280 5.161 0.119 5.281 -0.001
R,R-3 5.530 5.652 -0.122 5.774 -0.244
S,S-3 4.540 4.442 0.098 4.496 0.044
R,S-3 5.100 5.219 -0.119 5.093 0.007
S,R-3 4.640 4.645 -0.005 4.697 -0.057
R,R-4 5.730 5.684 0.046 5.764 -0.034
S,S-4 4.540 4.465 0.075 4.435 0.105
R,S-4 5.220 5.242 -0.022 5.033 0.187
S,R-4 4.510 4.677 -0.167 4.690 -0.180
R,R-5 6.620 6.805 -0.185 6.787 -0.167
S,S-5 5.600 5.528 0.072 5.520 0.080
R,S-5 6.470 6.305 0.165 6.129 0.341
S,R-5 5.750 5.798 -0.048 5.745 0.005
R,R-6 5.030 5.082 -0.052 5.189 -0.159
S,S-6 4.250 3.920 0.330 4.062 0.188
R,S-6 4.500 4.676 -0.176 4.380 0.120
S,R-6 4.000 4.093 -0.093 4.061 -0.061
R-7 4.980 5.268 -0.288 5.223 -0.243
 S-7 4.690 4.478 0.212 4.531 0.159
aObserved β2-AR binding affinity values taken from ref. 
5 bPredicted binding affinity values from Eq.6. cPredicted binding affi-
nity values from Eq.7.
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CONCLUSIONS
The drugs with β2-AR agonist action are used in the treat-
ment of asthma, but they may also be useful in the treat-
ment of congestive heart failure. Therefore, this in silico 
method has been applied to predict the binding affinities of 
the fenoterol stereoisomers with the β2-AR receptor. In this 
work, it has been shown that non-stochastic and stochas-
tic atom-based 3D-ciral quadratic indices are quite ver-
satile and can be applied in 3D-QSAR studies; the QSAR 
models obtained with our approach compare favourably 
with the CoMFA method. Although these are only pre-
liminary results and more studies are necessary to design 
new β2-AR agonists, the present work demonstrates in a 
straightforward way how 3D-chiral quadratic indices can 
be used to predict the affinity of a given chemical with the 
β2-adrenoceptor.
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